Sarepta Therapeutics | SRPT - Debt


Sarepta Therapeutics reported $1.04B in Debt for its fiscal quarter ending in March of 2026.





Debt Change Date
Acadia Pharmaceuticals USD 50.79M 1.39M Mar/2026
Agios Pharmaceuticals USD 35.74M 4.46M Mar/2026
Alnylam Pharmaceuticals USD 2.48B 1.21B Sep/2026
Amgen USD 57.32B 2.72B Mar/2026
BioCryst Pharmaceuticals USD 828.6M 510K Dec/2024
Biogen USD 7.69B 398.3M Sep/2026
BioMarin Pharmaceutical USD 4.2B 2.76B Jun/2026
Capricor Therapeutics USD 3.38M 0 Mar/2025
Daiichi Sankyo JPY 500.48B 200B Jun/2026
Eli Lilly USD 54.91B 11.54B Jun/2026
Gilead Sciences USD 26.25B 4.07B Jun/2026
Incyte USD 38.27M 1.16M Jun/2026
Insmed USD 544.86M 180.93M Sep/2026
Ionis Pharmaceuticals USD 1.91B 425.5M Jun/2026
Moderna USD 1.3B 7M Mar/2026
Nektar Therapeutics USD 0 0 Jun/2022
Neurocrine Biosciences USD 401.8M 4.4M Jun/2026
Novavax USD 233.31M 4.23M Sep/2024
Pfizer USD 63.19B 536M Jun/2026
PTC Therapeutics USD 2.84B 2.15B Sep/2026
Regeneron Pharmaceuticals USD 2.71B 400K Jun/2026
Roche Holding CHF 33.03B 1.41B Jun/2025
Sangamo BioSciences USD 0 0 Jun/2022
Sanofi EUR 23.58B 3.56B Jun/2026
Sarepta Therapeutics USD 1.04B 3.08M Mar/2026
Tectonic Therapeutic USD 876K 115K Dec/2024
Ultragenyx Pharmaceutical USD 36M 2.17M Dec/2025
Vertex Pharmaceuticals USD 1.98B 8.9M Jun/2026